Correlation of clinical signs and symptoms of Behçet's disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR).
Behçet’s disease
IBDDAM
Neutrophil to lymphocyte ratio
Ocular manifestation
Platelet to lymphocyte ratio
Journal
Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
05
02
2021
accepted:
10
04
2021
pubmed:
11
6
2021
medline:
27
1
2022
entrez:
10
6
2021
Statut:
ppublish
Résumé
Behçet's disease (BD) is a chronic disorder that involves multiple organs and is pathologically considered as a form of vasculitis. The current study aims to assess the metric properties of platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in assessing BD disease activity. Three-hundred-nineteen patients with BD were enrolled in this cross-sectional study. Demographic and epidemiological data, including IBDDAM, time since the onset, and medication and manifestation history were recorded. Complete blood counts (CBC), NLR, and PLR were assessed by analyzing blood samples. On the last visit, patients were assessed for active manifestations of disease. IBDDAM and ocular IBDAAM scores were calculated for activity of disease in each patient. Both PLR and NLR were higher in patients with active BD (Mann-Whitney U test, p-value < 0.05). Patients with active ocular manifestation had significantly higher NLR and PLR (Mann-Whitney U test, p-value < 0.05). These ratios, however, were not associated with other active BD manifestations. A value of NLR > 2.58 had 46% sensitivity and 85% specificity for the diagnosis of active ocular manifestations (AUC: 0.690). NLR had a significant, though, weak positive correlation with IBDDAM (Spearman's rho = 0.162; p-value < 0.05) and ocular IBDDAM (Spearman's rho = 0.159; p-value < 0.05). Active Behçet's presented with higher NLR and PLR ratios; however, there was only a modest correlation between NLR and BD activity (IBDDAM score). Also, NLR and PLR have significant relationship with ocular features of BD patients.
Identifiants
pubmed: 34109535
doi: 10.1007/s12026-021-09194-4
pii: 10.1007/s12026-021-09194-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
363-371Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Emmi G, Silvestri E, Squatrito D, D’Elios MM, Ciucciarelli L, Prisco D, et al. Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med. 2014;9(3):257–65.
doi: 10.1007/s11739-013-1036-5
Davatchi F, Chams-Davatchi C, Ghodsi Z, Shahram F, Nadji A, Shams H, et al. Diagnostic value of pathergy test in Behcet’s disease according to the change of incidence over the time. Clin Rheumatol. 2011;30(9):1151–5.
doi: 10.1007/s10067-011-1694-5
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD), Assaad-Khalil S, Calamia K, Crook J, Sadeghi-Abdollahi B, Schirmer M, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.
doi: 10.1111/jdv.12107
Seyahi E. Behçet’s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016;30(2):279–95.
doi: 10.1016/j.berh.2016.08.002
Shen Y, Ma H-F, Luo D, Guan J-L. The T-SPOT. TB assay used for screening and monitoring of latent tuberculosis infection in patients with Behçet’s disease pre-and post-anti-TNF treatment: a retrospective study. J Chin Med Assoc. 2019;82(5):375–80.
doi: 10.1097/JCMA.0000000000000071
Hu C-J, Pan J-B, Song G, Wen X-T, Wu Z-Y, Chen S, et al. Identification of novel biomarkers for Behcet disease diagnosis using human proteome microarray approach. Mol Cell Proteomics. 2017;16(2):147–56.
doi: 10.1074/mcp.M116.061002
Masoumi M, Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, et al. The value of ESR, CRP, and the Iran Behcet’s Disease Dynamic Activity Measure (IBDDAM ) in differentiating the active or inactive phases for the manifestations of Behcet’s disease. Jacobs J Orthop Rheumatol. 2018;4(1).
Türsen Ü. Pathophysiology of the Behcet's Disease. Pathol Res Int. 2012;2012.
Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med. 2019;39(4):345–57.
doi: 10.3343/alm.2019.39.4.345
Qin B, Ma N, Tang Q, Wei T, Yang M, Fu H, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2016;26(3):372–6.
doi: 10.3109/14397595.2015.1091136
Seng JJB, Kwan YH, Low LL, Thumboo J, Fong WSW. Role of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and mean platelet volume (MPV) in assessing disease control in Asian patients with axial spondyloarthritis. Biomarkers. 2018;23(4):335–8.
doi: 10.1080/1354750X.2018.1425916
Yang Z, Zhang Z, Lin F, Ren Y, Liu D, Zhong R, et al. Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil-lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS. 2017;125(10):863–71.
doi: 10.1111/apm.12722
Alexander N. Reference values of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in healthy adults in north central Nigeria. J Blood Lymph. 2016;6(1):143.
Hally KE, La Flamme AC, Harding SA, Larsen PD. Platelets regulate leucocyte responses to Toll-like receptor stimulation. Clin Transl Immunol. 2018;7(7):e1036.
doi: 10.1002/cti2.1036
Koiwa M, Goto S, Takahashi K, Kamada T, Takai S, Nakamura H. Neutrophil/lymphocyte ratio in patients with rheumatoid arthritis treated with biological agents. J Nippon Med Sch. 2016;83(3):118–24.
doi: 10.1272/jnms.83.118
Racz JM, Cleghorn MC, Jimenez MC, Atenafu EG, Jackson TD, Okrainec A, et al. Predictive ability of blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in gastrointestinal stromal tumors. Ann Surg Oncol. 2015;22(7):2343–50.
doi: 10.1245/s10434-014-4265-6
Li X, Chen Z-H, Xing Y-F, Wang T-T, Wu D-H, Wen J-Y, et al. Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumor Biol. 2015;36(4):2263–9.
doi: 10.1007/s13277-014-2833-9
Wu Y, Chen Y, Yang X, Chen L, Yang Y. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol. 2016;36:94–9.
doi: 10.1016/j.intimp.2016.04.006
Alan S, Tuna S, Türkoğlu EB. The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behcet’s syndrome. Kaohsiung J Med Sci. 2015;31(12):626–31.
doi: 10.1016/j.kjms.2015.10.010
Balta S, Celik T, Mikhailidis DP, Ozturk C, Demirkol S, Aparci M, et al. The relation between atherosclerosis and the neutrophil–lymphocyte ratio. Clin Appl Thromb Hemost. 2016;22(5):405–11.
doi: 10.1177/1076029615569568
Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet’s disease: which and when to use? Clin Rheumatol. 2018;37(10):2811–7.
doi: 10.1007/s10067-018-4194-z
Ozturk C, Balta S, Balta I, Demirkol S, Celik T, Turker T, et al. Neutrophil–lymphocyte ratio and carotid–intima media thickness in patients with Behcet disease without cardiovascular involvement. Angiology. 2015;66(3):291–6.
doi: 10.1177/0003319714527638
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.
doi: 10.1371/journal.pmed.0040296
Jamshidi A. The accuracy of IBDDAM (Iran Behcet’s disease dynamic activity measure) in the treatment evaluation of Behcet’s disease. APLAR J Rheumatol. 2001;4:161–3.
Jamshidi FS AR, Davatchi F, Akbarian M, Gharibdoost F, Nadji A. The accuracy of IBDDAM in the treatment evaluation of Behcet’s disease. Revue du Rhumatisme (Engl Ed). 1996;63(7–8):541.
International Study Group for Behçet’s D. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335(8697):1078–80.
Celikbilek M, Dogan S, Ozbakır O, Zararsız G, Kücük H, Gürsoy S, et al. Neutrophil–lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal. 2013;27(1):72–6.
doi: 10.1002/jcla.21564
Pan L, Du J, Li T, Liao H. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu’s arteritis: a case-control study. BMJ Open. 2017;7(4):e014451.
doi: 10.1136/bmjopen-2016-014451
Sönmez O, Ertaş G, Bacaksız A, Tasal A, Erdoğan E, Asoğlu E, et al. Relation of neutrophil-to-lymphocyte ratio with the presence and complexity of coronary artery disease: an observational study. Anadolu Kardiyol Derg. 2013;13(7):662–7.
pubmed: 23912788
Turkmen K, Erdur FM, Ozcicek F, Ozcicek A, Akbas EM, Ozbicer A, et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013;17(3):391–6.
doi: 10.1111/hdi.12040
Surmiak M, Hubalewska-Mazgaj M, Wawrzycka-Adamczyk K, Szczeklik W, Musiał J, Brzozowski T, et al. Neutrophil-related and serum biomarkers in granulomatosis with polyangiitis support extracellular traps mechanism of the disease. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S98-104.
pubmed: 27192020
Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11):1478–93.
doi: 10.2174/138161212799504731
Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci. 2009;54(4):842–7.
doi: 10.1007/s10620-008-0436-2
Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behçet’s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol. 2019;10:1085.
doi: 10.3389/fimmu.2019.01085
Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75(3):291–4.
doi: 10.1016/j.jbspin.2007.06.016
Tecer D, Sezgin M, Kanık A, İncel NA, Çimen ÖB, Biçer A, et al. Can mean platelet volume and red blood cell distribution width show disease activity in rheumatoid arthritis? Biomark Med. 2016;10(9):967–74.
doi: 10.2217/bmm-2016-0148
Emmi G, Silvestri E, Della Bella C, Grassi A, Benagiano M, Cianchi F, et al. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease. Medicine. 2016;95(49).
Jiang Y, Zang M, Li S. Serum PLR and LMR in Behçet's disease: can they show the disease activity?. Medicine. 2017;96(21).
Avci A, Avci D, Erden F, Ragip E, Cetinkaya A, Ozyurt K, et al. Can we use the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet’s disease? Ther Clin Risk Manag. 2017;13:881.
doi: 10.2147/TCRM.S135260